MedTrace Logo

A Study Evaluating 3-Level OLIF Spine Fusion

NCT03896347 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2023-07-20

No results posted yet for this study

Summary

The purpose of this study is to assess clinical and radiographic outcomes in patients who undergo three-level oblique lateral lumbar interbody fusion (OLIF) using ViBone, demineralized bone matrix (DBM), and bone morphogenetic protein (BMP). One product will be used on each level. Subjects will be followed for 12 months following surgery to assess degree of mineralization via computed tomography (CT) scan at 6 and 12 months, mean time to fusion, and maturation of fusion mass postoperatively via x-ray radiograph.

Conditions

  • Spondylolisthesis
  • Retrolisthesis
  • Degenerative Disc Disease

Interventions

OTHER

ViBone®

Viable bone allograft

OTHER

Demineralized Bone Matrix

Demineralized Bone Matrix

OTHER

Bone Morphogenetic Protein

Bone Morphogenetic Protein

Sponsors & Collaborators

  • Elutia Inc.

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2020-02-07
Completion
2020-02-13

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03896347 on ClinicalTrials.gov